|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_on1353781962 |
| 003 |
OCoLC |
| 005 |
20231120010717.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
220801s2023 maua ob 001 0 eng d |
| 040 |
|
|
|a UKMGB
|b eng
|e rda
|e pn
|c UKMGB
|d YDX
|d UKAHL
|d OPELS
|d OCLCF
|d YDX
|d N$T
|d AU@
|d OCLCO
|
| 015 |
|
|
|a GBC2D7682
|2 bnb
|
| 016 |
7 |
|
|a 020702618
|2 Uk
|
| 019 |
|
|
|a 1346350240
|a 1352015242
|a 1374132013
|
| 020 |
|
|
|a 0323855768
|q electronic publication
|
| 020 |
|
|
|a 9780323855761
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323858816
|q paperback
|
| 020 |
|
|
|a 0323858813
|
| 020 |
|
|
|a 9780323858816
|
| 035 |
|
|
|a (OCoLC)1353781962
|z (OCoLC)1346350240
|z (OCoLC)1352015242
|z (OCoLC)1374132013
|
| 050 |
|
4 |
|a RC271.C5
|b A78 2023
|
| 082 |
0 |
4 |
|a 616.994061
|2 23
|
| 245 |
0 |
0 |
|a Aptamers engineered nanocarriers for cancer therapy /
|c edited by Prashant Kesharwani.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Woodhead Publishing,
|c [2023]
|
| 300 |
|
|
|a 1 online resource :
|b illustrations (black and white, and colour).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Woodhead Publishing series in biomaterials
|
| 500 |
|
|
|a 1. Cell-SELEX technology for aptamer selection<br>2. Biological characteristics of aptamers<br>3. Mechanisms of multi-drug resistance of cancer<br>4. Relevance of aptamers as targeting ligands for anticancer therapies<br>5. Aptamers as smart ligands for nano-carriers cancer targeting<br>6. Aptamer-functionalized liposomes for targeted cancer therapy<br>7. Aptamer-functionalized micelles for targeted cancer therapy<br>8. Aptamer-functionalized nanoparticles for targeted cancer therapy<br>9. Aptamer-functionalized PLGA nanoparticles for targeted cancer therapy<br>10. Aptamer-functionalized silica nanoparticles for targeted cancer therapy<br>11. Aptamer-functionalized gold nanoparticles for targeted cancer therapy<br>12. Aptamer-functionalized dendrimers for targeted cancer therapy<br>13. Aptamer-functionalized carbon nanotubes for targeted cancer therapy<br>14. Aptamer-functionalized quantum dots for targeted cancer therapy<br>15. Cancer immunotherapy via nucleic acid aptamers<br>16. Aptamer-based imaging and diagnostics for cancer cells<br>17. Microdevice-based aptamer sensors<br>18. Aptamer-based microfluidics for circulating tumor cells<br>19. Aptamer-based theranostic approaches for treatment of cancer<br>20. Challenges of aptamers as targeting ligands for anticancer therapies<br>21. Clinical use and future perspective of aptamers
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
|
|
|a Description based on online resource; title from digital title page (viewed on June 12, 2023).
|
| 650 |
|
0 |
|a Cancer
|x Chemotherapy.
|
| 650 |
|
0 |
|a Drug delivery systems.
|
| 650 |
|
0 |
|a Nanomedicine.
|
| 650 |
|
0 |
|a Oligonucleotides.
|
| 650 |
|
2 |
|a Drug Delivery Systems
|0 (DNLM)D016503
|
| 650 |
|
2 |
|a Nanomedicine
|0 (DNLM)D050997
|
| 650 |
|
2 |
|a Oligonucleotides
|0 (DNLM)D009841
|
| 650 |
|
6 |
|a Cancer
|x Chimioth�erapie.
|0 (CaQQLa)201-0004691
|
| 650 |
|
6 |
|a Syst�emes d'administration de m�edicaments.
|0 (CaQQLa)000260397
|
| 650 |
|
6 |
|a Nanom�edecine.
|0 (CaQQLa)201-0448752
|
| 650 |
|
6 |
|a Oligonucl�eotides.
|0 (CaQQLa)201-0162366
|
| 650 |
|
7 |
|a Cancer
|x Chemotherapy
|2 fast
|0 (OCoLC)fst00845327
|
| 650 |
|
7 |
|a Drug delivery systems
|2 fast
|0 (OCoLC)fst00898667
|
| 650 |
|
7 |
|a Nanomedicine
|2 fast
|0 (OCoLC)fst01744350
|
| 650 |
|
7 |
|a Oligonucleotides
|2 fast
|0 (OCoLC)fst01045453
|
| 700 |
1 |
|
|a Kesharwani, Prashant,
|e editor.
|1 https://isni.org/isni/0000000497260609
|
| 776 |
0 |
8 |
|i Print version:
|z 9780323858816
|
| 830 |
|
0 |
|a Woodhead Publishing series in biomaterials.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780323858816
|z Texto completo
|
